CSN6 expression is associated with pancreatic cancer progression and predicts poor prognosis

References

• Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7:163–172. PMID:20101258. doi:10.1038/nrclinonc.2009.236.
   PubMed Web of Science ®Google Scholar
• Lomberk G, Blum Y, Nicolle R, Nair A, Gaonkar KS, Marisa L, Mathison A, Sun Z, Yan H, Elarouci N, et al. Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. Nat Commun. 2018;9:1978. PMID:29773832. doi:10.1038/s41467-018-04383-6.
   PubMed Web of Science ®Google Scholar
• Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–2921. PMID:24840647. doi:10.1158/0008-5472.CAN-14-0155.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. PMID:29313949. doi:10.3322/caac.21442.
   PubMed Web of Science ®Google Scholar
• Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47–52. PMID:26909576. doi:10.1038/nature16965.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388:73–85. PMID:26830752. doi:10.1016/S0140-6736(16)00141-0.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. PMID:21376230. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer. 2006;6:776–788. PMID:16990855. doi:10.1038/nrc1994.
   PubMed Web of Science ®Google Scholar
• Azzolin L, Zanconato F, Bresolin S, Forcato M, Basso G, Bicciato S, Cordenonsi M, Piccolo S. Role of TAZ as mediator of Wnt signaling. Cell. 2012;151:1443–1456. PMID:23245942. doi:10.1016/j.cell.2012.11.027.
   PubMed Web of Science ®Google Scholar
• Chen B, Zhao R, Su CH, Linan M, Tseng C, Phan L, Fang L, Yang HY, Yang H, Wang W, et al. CDK inhibitor p57 (Kip2) is negatively regulated by COP9 signalosome subunit 6. Cell Cycle. 2012;11:4633–4641. PMID:23187808. doi:10.4161/cc.22887.
   PubMed Web of Science ®Google Scholar
• Choi HH, Gully C, Su CH, Velazquez-Torres G, Chou PC, Tseng C, Zhao R, Phan L, Shaiken T, Chen J, et al. COP9 signalosome subunit 6 stabilizes COP1, which functions as an E3 ubiquitin ligase for 14-3-3σ. Oncogene. 2011;30:4791–4801. PMID:21625211. doi:10.1038/onc.2011.192.
   PubMed Web of Science ®Google Scholar
• Shin J, Phan L, Chen J, Lu Z, Lee MH. CSN6 positively regulates c-Jun in a MEKK1-dependent manner. Cell Cycle. 2015;14:3079–3087. PMID:26237449. doi:10.1080/15384101.2015.1078030.
   PubMed Web of Science ®Google Scholar
• Xue Y, Chen J, Choi HH, Phan L, Chou PC, Zhao R, Yang H, Santiago J, Liu M, Yeung GE, et al. HER2-Akt signaling in regulating COP9 signalsome subunit 6 and p53. Cell Cycle. 2012;11:4181–4190. PMID:23095642. doi:10.4161/cc.22413.
   PubMed Web of Science ®Google Scholar
• Yang L, Liu Y, Wang M, Qian Y, Dong X, Gu H, Wang H, Guo S, Hisamitsu T. Quercetin-induced apoptosis of HT-29 colon cancer cells via inhibition of the Akt-CSN6-Myc signaling axis. Mol Med Rep. 2016;14:4559–4566. PMID:27748879. doi:10.3892/mmr.2016.5818.
   PubMed Web of Science ®Google Scholar
• Chen J, Shin JH, Zhao R, Phan L, Wang H, Xue Y, Post SM, Ho CH, Chen JS, Wang E, et al. CSN6 drives carcinogenesis by positively regulating Myc stability. Nat Commun. 2014;5:5384. PMID:25395170. doi:10.1038/ncomms6384.
   PubMed Web of Science ®Google Scholar
• Choi HH, Guma S, Fang L, Phan L, Ivan C, Baggerly K, Sood A, Lee MH. Regulating the stability and localization of CDK inhibitor p27(Kip1) via CSN6-COP1 axis. Cell Cycle. 2015;14:2265–2273. PMID:25945542. doi:10.1080/15384101.2015.1046655.
   PubMed Web of Science ®Google Scholar
• Choi HH, CH S, Fang L, Zhang J, Yeung SC, Lee MH. CSN6 deregulation impairs genome integrity in a COP1-dependent pathway. Oncotarget. 2015;6:11779–11793. PMID:25957415. doi:10.18632/oncotarget.3151.
   PubMedGoogle Scholar
• Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, Bresolin S, Frasson C, Basso G, Guzzardo V, et al. YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. Cell. 2014;158:157–170. PMID:24976009. doi:10.1016/j.cell.2014.06.013.
   PubMed Web of Science ®Google Scholar
• Wang W, Tang M, Zhang L, Xu X, Qi X, Yang Y, Jin F, Chen B. Clinical implications of CSN6 protein expression and correlation with mutant-type P53 protein in breast cancer. Jpn J Clin Oncol. 2013;43:1170–1176. PMID:24106298. doi:10.1093/jjco/hyt148.
   PubMed Web of Science ®Google Scholar
• Echalier A, Pan Y, Birol M, Tavernier N, Pintard L, Hoh F, Ebel C, Galophe N, Claret FX, Dumas C. Insights into the regulation of the human COP9 signalosome catalytic subunit, CSN5/Jab1. Proc Natl Acad Sci U S A. 2013;110:1273–1278. PMID:23288897. doi:10.1073/pnas.1209345110.
   PubMed Web of Science ®Google Scholar
• Fang L, Lu W, Choi HH, Yeung SC, Tung JY, Hsiao CD, Fuentes-Mattei E, Menter D, Chen C, Wang L, et al. ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development. Cancer Cell. 2015;28:183–197. PMID:26267535. doi:10.1016/j.ccell.2015.07.004.
   PubMed Web of Science ®Google Scholar
• Gao S, Fang L, Phan LM, Qdaisat A, Yeung SC, Lee MH. COP9 signalosome subunit 6 (CSN6) regulates E6AP/UBE3A in cervical cancer. Oncotarget. 2015;6:28026–28041. PMID:26318036. doi:10.18632/oncotarget.4731.
   PubMedGoogle Scholar
• Guo H, Jing L, Cheng Y, Atsaves V, Lv Y, Wu T, Su R, Zhang Y, Zhang R, Liu W, et al. Down-regulation of the cyclin-dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis. Hepatology. 2016;63:898–913. PMID:26606000. doi:10.1002/hep.28372.
   PubMed Web of Science ®Google Scholar
• Hou J, Deng Q, Zhou J, Zou J, Zhang Y, Tan P, Zhang W, Cui H. CSN6 controls the proliferation and metastasis of glioblastoma by CHIP-mediated degradation of EGFR. Oncogene. 2017;36:1134–1144. PMID:27546621. doi:10.1038/onc.2016.280.
   PubMed Web of Science ®Google Scholar
• Wen D, Liao T, Ma B, Qu N, Shi RL, Lu ZW, Wang YL, Wei WJ, Ji QH. Downregulation of CSN6 attenuates papillary thyroid carcinoma progression by reducing Wnt/β-catenin signaling and sensitizes cancer cells to FH535 therapy. Cancer Med. 2018;7:285–296. PMID:29341469. doi:10.1002/cam4.1272.
   PubMed Web of Science ®Google Scholar
• Zhang SN, Pei DS, Zheng JN. The COP9 signalosome subunit 6 (CSN6): a potential oncogene. Cell Div. 2013;8:14. PMID:24286178. doi:10.1186/1747-1028-8-14.
   Web of Science ®Google Scholar
• Choi HH, Lee MH. CSN6-COP1 axis in cancer. Aging (Albany NY). 2015;7(7):461–462. PMID:26186957. doi:10.18632/aging.100778.
   PubMedGoogle Scholar
• Iyer SV, Iwakuma T. A novel link between the HER2-Akt and MDM2-p53 pathways via CSN6. Cell Cycle. 2012;11:4112. PMID:23099920. doi:10.4161/cc.22606.
   PubMed Web of Science ®Google Scholar
• Zhao R, Yeung SC, Chen J, Iwakuma T, Su CH, Chen B, Qu C, Zhang F, Chen YT, Lin YL, et al. Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest. 2011;121:851–865. PMID:21317535. doi:10.1172/JCI44111.
   PubMed Web of Science ®Google Scholar
• Villafañez F, García IA, Carbajosa S, Pansa MF, Mansilla S, Llorens MC, Angiolini V, Guantay L, Jacobs H, Madauss KP, et al. AKT inhibition impairs PCNA ubiquitylation and triggers synthetic lethality in homologous recombination-deficient cells submitted to replication stress. Oncogene. 2019;38:4310–4324. PMID:30705406. doi:10.1038/s41388-019-0724-7.
   PubMed Web of Science ®Google Scholar
• Wang SC. PCNA: a silent housekeeper or a potential therapeutic target. Trends Pharmacol Sci. 2014;35:178–186. PMID:24655521. doi:10.1016/j.tips.2014.02.004.
   PubMed Web of Science ®Google Scholar
• Badea L, Herlea V, Dima SO, Dumitrascu T, Popescu I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology. 2008;55:2016–2027. PMID:19260470.
   PubMedGoogle Scholar
• Whitcomb DC, Shelton CA, Brand RE. Genetics and Genetic Testing in Pancreatic Cancer. Gastroenterology. 2015;149:1252–64.e4. PMID:26255042. doi:10.1053/j.gastro.2015.07.057.
   PubMed Web of Science ®Google Scholar
• Ge Z, Leighton JS, Wang Y, Peng X, Chen Z, Chen H, Sun Y, Yao F, Li J, Zhang H, et al. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. Cell Rep. 2018;23:213–26.e3. PMID:29617661. doi:10.1016/j.celrep.2018.03.047.
   PubMed Web of Science ®Google Scholar
• Schmid JA, Berti M, Walser F, Raso MC, Schmid F, Krietsch J, Stoy H, Zwicky K, Ursich S, Freire R, et al. Histone Ubiquitination by the DNA Damage Response Is Required for Efficient DNA Replication in Unperturbed S Phase. Mol Cell. 2018;71:897–910.e8. PMID:30122534. doi:10.1016/j.molcel.2018.07.011.
   PubMed Web of Science ®Google Scholar
• Seo JH, Agarwal E, Bryant KG, Caino MC, Kim ET, Kossenkov AV, Tang HY, Languino LR, Gabrilovich DI, Cohen AR, et al. Syntaphilin Ubiquitination Regulates Mitochondrial Dynamics and Tumor Cell Movements. Cancer Res. 2018;78:4215–4228. PMID:29898993. doi:10.1158/0008-5472.CAN-18-0595.
   PubMed Web of Science ®Google Scholar
• Wang X, Liu Z, Zhang L, Yang Z, Chen X, Luo J, Zhou Z, Mei X, Yu X, Shao Z, et al. Targeting deubiquitinase USP28 for cancer therapy. Cell Death Dis. 2018;9:186. PMID:29415985. doi:10.1038/s41419-017-0208-z.
   PubMed Web of Science ®Google Scholar
• Lee MH, Zhao R, Phan L, Yeung SC. Roles of COP9 signalosome in cancer. Cell Cycle. 2011;10:3057–3066. PMID:21876386. doi:10.4161/cc.10.18.17320.
   PubMed Web of Science ®Google Scholar
• Fraile JM, Quesada V, Rodríguez D, Freije JM, López-Otín C. Deubiquitinases in cancer: new functions and therapeutic options. Oncogene. 2012;31:2373–2388. PMID:21996736. doi:10.1038/onc.2011.443.
   PubMed Web of Science ®Google Scholar
• Shemesh A, Kundu K, Peleg R, Yossef R, Kaplanov I, Ghosh S, Khrapunsky Y, Gershoni-Yahalom O, Rabinski T, Cerwenka A, et al. NKp44-Derived Peptide Binds Proliferating Cell Nuclear Antigen and Mediates Tumor Cell Death. Front Immunol. 2018;9:1114. PMID:29875773. doi:10.3389/fimmu.2018.01114.
   PubMed Web of Science ®Google Scholar
• Chen LY, Cheng CS, Qu C, Wang P, Chen H, Meng ZQ, Chen Z. Overexpression of CBX3 in Pancreatic Adenocarcinoma Promotes Cell Cycle Transition-Associated Tumor Progression. Int J Mol Sci. 2018;19. PMID:29903985. doi:10.3390/ijms19061768.
   Web of Science ®Google Scholar
• Borgquist S, Anagnostaki L, Jirström K, Landberg G, Manjer J. Breast tumours following combined hormone replacement therapy express favourable prognostic factors. Int J Cancer. 2007;120:2202–2207. PMID:17278089. doi:10.1002/ijc.22542.
   PubMed Web of Science ®Google Scholar
• Qin Z, Lu M, Xu X, Hanna M, Shiomi N, Xiao W. DNA-damage tolerance mediated by PCNA*Ub fusions in human cells is dependent on Rev1 but not Polη. Nucleic Acids Res. 2013;41:7356–7369. PMID:23761444. doi:10.1093/nar/gkt542.
   PubMed Web of Science ®Google Scholar
• Kardosh A, Lichtensztajn DY, Gubens MA, Kunz PL, Fisher GA, Clarke CA. Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study. Pancreas. 2018;47:958–966. PMID:30074526. doi:10.1097/MPA.0000000000001133.
   PubMed Web of Science ®Google Scholar
• Ma W, Li T, Wu S, Li J, Wang X, Li H. LOX and ACSL5 as potential relapse markers for pancreatic cancer patients. Cancer Biol Ther. 2019;1–12. PMID:30712446. doi:10.1080/15384047.2018.1564565.
   PubMed Web of Science ®Google Scholar
• Hu D, Ansari D, Zhou Q, Sasor A, Said HK, Andersson R. Galectin 4 is a biomarker for early recurrence and death after surgical resection for pancreatic ductal adenocarcinoma. Scand J Gastroenterol. 2019;1–6. PMID:30663442. doi:10.1080/00365521.2018.1561937.
   PubMed Web of Science ®Google Scholar
• Aoyama T, Yamamoto N, Kamiya M, Murakawa M, Tamagawa H, Sawazaki S, Numata M, Shiozawa M, Kobayashi S, Ueno M, et al. The Lymph Node Ratio Is an Independent Prognostic Factor in Pancreatic Cancer Patients Who Receive Curative Resection Followed by Adjuvant Chemotherapy. Anticancer Res. 2018;38:4877–4882. PMID:30061263. doi:10.21873/anticanres.12801.
   PubMed Web of Science ®Google Scholar